Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections

Severe Sepsis Clinical Trial

— EVAMICA  

Official title:

Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00709358
• Other study ID #: P070308
• Status: Completed
• Phase: Phase 4
• First received: July 2, 2008
• Last updated: December 26, 2011
• Start date: May 2008
• Est. completion date: September 2010

Study information

• Verified date: May 2011
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The primary purpose is to improve and quicken the microbial diagnosis in severe infections, since only one third of the cases are documented by blood cultures and adequate anti-infective therapy in the 48 hours reduced mortality and morbidity.

Our hypothesis is that detection of microbial DNA in blood by real time PCR may increase the number of cases diagnosed for bacteraemia or fungemia and shorten the time to positive results, which will provide information for an adequate anti-infectious therapy.

Description:

We will evaluate the advantage of adding the molecular test to the microbial investigations usually done (blood cultures and others) in cases of febrile neutropenia, suspicion of infective endocarditis and severe sepsis in intensive care units.

This is a prospective study conducted in 18 sites (7 in the Paris area and 11 all over France) which will enrolled about 2000 patients over 18 years. Sites are randomized for starting with a 6-month period performing the test or 6-month period without the test (control time with the standard of care).

Primary outcome are the number of patients with documented bacteraemia or fungemia. Secondary outcome are (1) the number of patients with an adequate anti-infective therapy and how long it happens after the diagnosis, (2) mortality, (3) new complicated infection, (4) number of investigations (microbial and non microbial) done for the etiological diagnosis, and global hospitalization costs.

The advantage of the new test will be evaluated per protocol and with an intend to treat analyses. We hypothesized that the new test will bring 15% more microbial diagnosis than the standard of care. Consequently, and according to the number of sites interested in the study, 166 to 2500 patients will be enrolled with 480 to 750 patients with febrile neutropenia, 1000 to 1500 patients with severe sepsis in Intensive Care Units (ICU). Patients with suspicion of infective endocarditis will be evaluated for the number of diagnosis of true endocarditis according to Duke Criteria, and the time to diagnosis.

Health economic evaluation will compare the costs of hospitalization, microbial investigations including the new test, other non clinical investigations and consequences on the organization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: September 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age= 18 years

• Written signed and dated inform consent

• First time with fever observed in a neutropenic patient

• Severe sepsis in a patient hospitalized in ICU

• Suspicion of infective endocarditis

• Microbial investigation from Monday to Friday

Exclusion Criteria:

• Not affiliated to Health Insurance (social security)

• Included in another interventional trial testing microbial DNA detection during the time "without Septifast®"

• Included in another clinical trial for which the clinician assumes that it will not be possible to prescribe an anti-infectious therapy adequately to microbial detection in the blood

• Patient previously included in the protocol

• Sepsis with a microbial diagnosis

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Endocarditis
• Febrile Neutropenia
• Neutropenia
• Severe Sepsis

Intervention

Other:
• Detection of microbial DNA in blood by SeptiFast®
The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps. Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours.
• detection of microbial DNA in blood by blood culture
A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.

Locations

Country	Name	City	State
France	CHU Henri Mondor	Créteil

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Hoffmann-La Roche

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of bacteraemia and of fungemia - overall - each condition		max Day 30	Yes
Secondary	Number of patients with adequate anti-infective therapy		at day 30	Yes
Secondary	Adequate anti-infective therapy		at 24h, 48h, > 48h	Yes
Secondary	Time between sampling for microbial investigation and positive results relevant for the diagnosis		between sampling for microbial investigation and positive results	Yes
Secondary	Mortality		at Day 30	Yes
Secondary	Sepsis chock, secondary infectious focus		at Day 30	Yes
Secondary	For neutropenia cases, number of patients who evaluated with a clinical focus of infection		at day 30	Yes
Secondary	Diagnosis of endocarditis		at Day 45	Yes
Secondary	Number of non clinical investigations (microbial and non microbial)		at day 30	Yes
Secondary	Length of hospital stay		at day 30	Yes